Sarepta Therapeutics Inc (SRPT)
129.53
+2.14
(+1.68%)
USD |
NASDAQ |
Apr 26, 14:34
Sarepta Therapeutics Free Cash Flow (Quarterly): -73.70M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -73.70M |
| September 30, 2023 | -155.62M |
| June 30, 2023 | -140.14M |
| March 31, 2023 | -218.88M |
| December 31, 2022 | -100.56M |
| September 30, 2022 | -74.42M |
| June 30, 2022 | -75.89M |
| March 31, 2022 | -106.73M |
| December 31, 2021 | -33.84M |
| September 30, 2021 | -133.57M |
| June 30, 2021 | -115.04M |
| March 31, 2021 | -201.52M |
| December 31, 2020 | -203.14M |
| September 30, 2020 | -263.49M |
| June 30, 2020 | -126.77M |
| March 31, 2020 | 618.67M |
| December 31, 2019 | -181.05M |
| September 30, 2019 | -76.86M |
| June 30, 2019 | -95.69M |
| March 31, 2019 | -162.50M |
| December 31, 2018 | -139.99M |
| September 30, 2018 | -134.49M |
| June 30, 2018 | -126.83M |
| March 31, 2018 | -48.51M |
| December 31, 2017 | -35.58M |
| Date | Value |
|---|---|
| September 30, 2017 | -65.66M |
| June 30, 2017 | -88.37M |
| March 31, 2017 | -63.60M |
| December 31, 2016 | -84.58M |
| September 30, 2016 | -61.78M |
| June 30, 2016 | -44.06M |
| March 31, 2016 | -62.27M |
| December 31, 2015 | -32.81M |
| September 30, 2015 | -47.80M |
| June 30, 2015 | -29.42M |
| March 31, 2015 | -44.27M |
| December 31, 2014 | -28.91M |
| September 30, 2014 | -48.22M |
| June 30, 2014 | -44.35M |
| March 31, 2014 | -33.88M |
| December 31, 2013 | -18.55M |
| September 30, 2013 | -21.56M |
| June 30, 2013 | -12.90M |
| March 31, 2013 | -15.46M |
| December 31, 2012 | -7.581M |
| September 30, 2012 | -7.886M |
| June 30, 2012 | -6.061M |
| March 31, 2012 | -9.311M |
| December 31, 2011 | -6.432M |
| September 30, 2011 | -7.843M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-263.49M
Minimum
Sep 2020
618.67M
Maximum
Mar 2020
-92.54M
Average
-115.04M
Median
Jun 2021
Free Cash Flow (Quarterly) Benchmarks
| PTC Therapeutics Inc | -128.75M |
| Vertex Pharmaceuticals Inc | 118.50M |
| Regenxbio Inc | -41.89M |
| CytomX Therapeutics Inc | -22.23M |
| Apellis Pharmaceuticals Inc | -97.97M |